J&J Remains Optimistic Despite 5% Decline In First-Quarter Device Sales

The company expects the COVID-19 pandemic will cost its device businesses between $4bn and $7bn in revenue in 2020, as most non-urgent procedures are postponed.

SC2004_JNJ Sign_1524542537_1200.jpg
• Source: shutterstock.com

More from Business

More from Medtech Insight